News

How Trump’s Second Term Could Reshape US-India Pharma Partnerships

Projections suggest that Trump’s “America First” agenda, coupled with his focus on reducing reliance on China, could create both opportunities and challenges for India’s drug manufacturers.

• By Pooja Chaturvedi Sah
• New Delhi
• Nov 08, 2024

News

With Donald Trump securing a second term as President of the United States, India’s pharmaceutical sector finds itself at a potential inflection point. Projections suggest that Trump’s “America First” agenda, coupled with his focus on reducing reliance on China, could create both opportunities and challenges for India’s drug manufacturers. 

While the shift in U.S. policy offers a promising pathway for expansion, Indian companies may also need to navigate complex trade dynamics and potential tariff changes. 

Expansion Potential for India’s Pharma Sector with “America First” Policies 

According to a recent report by Elara Capital, several sectors in India, including pharmaceuticals, IT, and defense, stand to gain from Trump’s second-term policies. Trump’s approach to trade, supply chain diversification, and decreased dependence on China could make India a strategic partner to support U.S. healthcare needs. By aiming to reduce Chinese imports, Trump is expected to encourage American firms to diversify supply chains for critical sectors. 

However, while this diversification effort aligns well with India’s strengths, potential tariff hikes and a protectionist trade stance may dampen some of these benefits. Indian companies may have to carefully adapt to new regulatory and trade terms to maximize the opportunity. 

India’s Pharma Industry Ready to Fill U.S. Supply Chain Gaps 

India’s pharmaceutical sector is especially well-suited to meet increased U.S. demand, particularly as Trump seeks to reduce reliance on Chinese suppliers. The “China+1” strategy, which encourages U.S. firms to establish alternative supplier bases alongside China, could open doors for India’s pharma sector. 

India’s well-established expertise in generics, active pharmaceutical ingredients (APIs), and biosimilars positions it as an ideal partner for the U.S. pharmaceutical market, where affordability and reliable production are priorities. By offering high-quality generics at competitive prices, Indian companies could help bridge critical supply gaps in the U.S., especially as U.S. companies look to strengthen their drug supply chains. 

Indian firms have historically been major suppliers of generics to the U.S. market, and this trend may intensify under Trump’s second term as American firms prioritize reliable partners for essential pharmaceuticals. 

Boosting U.S. Partnerships Amid Favorable Trade Dynamics 

India’s existing trade relations and its strong record in pharma exports provide a solid foundation for increased collaboration with the U.S. India’s pharmaceutical industry has long been recognized as a trusted provider of affordable drugs, especially in generics, where it dominates global markets. 

With Trump’s renewed emphasis on U.S. manufacturing and drug supply security, India is well-positioned to capitalize on this longstanding partnership. While changes to tariffs and trade terms are anticipated, experts suggest that Trump’s administration is likely to favor allies and partners positioned as trusted contributors to the global supply chain. This favorable positioning could help Indian pharmaceutical companies expand their market share in the U.S. even as new policies evolve. 

As India’s capabilities in generics and biosimilars align with Trump’s vision for affordable healthcare, the sector is primed to play a more prominent role in addressing U.S. healthcare demands. 

Currency and Interest Rate Pressures Loom 

While the opportunities are considerable, Trump’s anticipated economic policies may present challenges for India. If the Federal Reserve takes a hawkish stance, as many expect, with a focus on controlling inflation, the resulting interest rate hikes could strengthen the U.S. dollar. 

For Indian pharma companies heavily reliant on U.S. exports, a stronger dollar could lead to rupee depreciation, creating currency exchange pressures and impacting revenue margins. In addition, a strong dollar combined with rising U.S. bond yields could affect the purchasing power of emerging markets like India, potentially reducing the affordability of pharmaceutical imports. 

Navigating Trade and Tariff Hurdles 

Even as India’s generic drug sector could benefit from continued demand for cost-effective healthcare solutions in the U.S., trade experts caution that Trump’s protectionist policies may introduce new obstacles. Should Trump choose to implement higher tariffs on Indian exports like pharmaceuticals, autos, and textiles, the price competitiveness of Indian products in the U.S. market could be undermined. For Indian pharmaceutical firms exporting to the U.S., higher customs duties could limit market access and profitability. 

Nevertheless, analysts at Elara Capital suggest that the administration’s focus on reducing dependence on China could bolster India’s role as an alternative supplier in key sectors like pharmaceuticals. “If the U.S. shifts its sourcing away from China, India could step in as a reliable supplier, but this hinges on navigating any new trade restrictions,” the report notes. 

FDA and Regulatory Landscape Remain Stable Amid Potential Trade Shifts 

Indian pharmaceutical companies exporting generics to the U.S. are also closely monitoring any potential changes within the U.S. Food and Drug Administration (FDA). For now, experts do not anticipate major regulatory overhauls under Trump. 

Additionally, the continued preservation of the Affordable Care Act (ACA) means that healthcare access for millions in the U.S. will likely remain intact, maintaining demand for affordable generic drugs, many of which Indian firms supply. This regulatory stability could provide Indian pharma companies with some predictability, even as they contend with potential tariff challenges. 

Strategic Moves in Biosimilars and Contract Manufacturing 

India’s pharmaceutical sector is set to benefit from new growth areas, particularly in biosimilars and advanced generics. Trump’s policies, which emphasize lower healthcare costs and secure medical supply chains, create a favorable environment for India’s contract development and manufacturing organizations (CDMOs). 

Known for cost efficiency, Indian CDMOs could capture a greater share of outsourced drug production as U.S. companies look for alternatives to Chinese suppliers. “India is well-positioned to capitalize on this demand for reliable, cost-effective drug manufacturing,” an Elara Capital analyst noted. 

Emerging Opportunities in Health Tech and Telemedicine 

While Trump’s policies primarily impact traditional pharma, India’s health tech and telemedicine sectors could find new growth opportunities as well. Although accessing the U.S. market in these areas remains challenging, there may be greater willingness to collaborate in telemedicine, remote diagnostics, and digital health solutions. 

India’s rapidly growing health tech ecosystem is poised to seize these emerging opportunities, which align with America’s diversified healthcare strategy. 

The Path Forward: A Growth Window for Indian Pharma 

Following Trump’s re-election, India’s pharmaceutical sector is preparing to strengthen its footprint in the U.S. market. The combination of favorable trade dynamics, currency advantages, and increasing demand for generics and biosimilars could propel India’s pharma industry toward significant growth. 

As American companies diversify their supply networks, India’s pharmaceutical expertise and cost competitiveness make it an attractive partner. While “America First” policies may introduce some trade tensions, they also present unique opportunities for Indian companies to expand their market presence in the U.S. If Trump’s anti-China stance and supply chain diversification priorities endure, Indian pharmaceutical companies are well-positioned to become influential players in the global healthcare supply chain. 

As the demand for affordable, high-quality drugs continues to grow, India’s pharma sector is prepared to play a key role, benefiting from both geopolitical shifts and economic developments. The full impact on India’s pharmaceutical industry will depend on how U.S. trade policies unfold and India’s ability to capitalize on this rare opening to become an indispensable player in American healthcare.